Latest Posts › Myriad

Share:

Examination of Myriad-Mayo Guidance Comments -- International Bioindustry Associations

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/12/2014 - Biotechnology Mayo v. Prometheus Myriad Myriad-Mayo Patent Litigation Patent-Eligible Subject Matter Patents Pharmaceutical Pharmaceutical Patents Public Comment Rulemaking Process USPTO

Examination of Myriad-Mayo Guidance Comments -- ACLU

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/6/2014 - ACLU Biotechnology Chemicals CLS Bank v Alice Corp Mayo v. Prometheus Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Public Comment Section 101 USPTO

Docs @ BIO: USPTO Provides Update on Myriad-Mayo Guidance

At last week's BIO International Convention in San Diego, Andrew Hirshfeld, USPTO Deputy Commissioner for Patent Examination Policy, and June Cohan, a Legal Advisor with the USPTO's Office of Patent Legal Administration, took...more

7/2/2014 - DNA Genetic Materials Guidance Update Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Public Comment Section 101 Stem cells USPTO

USPTO Extends Deadline for Providing Feedback on Myriad-Mayo Guidance

As we reported earlier this week, the period for submitting written comments to the U.S. Patent and Trademark Office regarding the Office's Myriad-Mayo guidance memorandum has been extended to July 31, 2014. The Office...more

6/30/2014 - Memorandum of Guidance Myriad Myriad-Mayo Patent Trial and Appeal Board Patent-Eligible Subject Matter Patents USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part II

Last Friday, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

5/15/2014 - Forum Myriad Patent Examinations Patent-Eligible Subject Matter Patents Public Comment SCOTUS USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part I

Last Friday, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

5/13/2014 - Guidance Update Myriad Patent Examinations Patent-Eligible Subject Matter Public Comment SCOTUS USPTO

In re Roslin Institute (Fed. Cir. 2014) - Dolly the Sheep Not Patent Eligible Subject Matter

Earlier today, the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board affirming the rejection of claims 155-159 and 164 of U.S. Application No. 09/225,233 as being directed to unpatentable subject...more

5/9/2014 - Genetic Materials Myriad Patent-Eligible Subject Matter Patents USPTO

USPTO Tries to Address Public Misunderstandings Regarding Myriad-Mayo Guidance

The U.S. Patent and Trademark Office spent the entire afternoon session of today's biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting focusing on the guidance memorandum for determining the subject...more

4/17/2014 - Biotechnology Myriad Patent-Eligible Subject Matter Pharmaceutical USPTO

More Q&A from Webinar on Top Patent Law Stories of 2013

On Tuesday, we presented a live webinar on the "Top Patent Law Stories of 2013." The webinar covered ten of the fourteen stories that made it onto Patent Docs seventh annual list of top biotech/pharma patent stories. Posts...more

1/24/2014 - 23andMe America Invents Act AMP v Myriad Biotechnology Bowman v Monsanto FTC v Actavis Innovation Act Life Sciences Monsanto Myriad Patent Infringement Patent Litigation Patent Reform Patent Trolls Patents Pharmaceutical SCOTUS

Top Stories of 2013: #7 to #10

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/2/2014 - Ambry Biotechnology BRCA DNA Human Genes Life Sciences Myriad Patent Litigation Patents Pharmaceutical

Amici Submit Brief in Support of Ambry Genetics and Gene by Gene

Last week, the American Civil Liberties Union (ACLU), ACLU of Utah Foundation, Inc., Public Patent Foundation (PUBPAT), Association for Molecular Pathology (AMP), Breast Cancer Action, and AARP submitted an amici curiae brief...more

8/28/2013 - ACLU Ambry AMP v Myriad Infringement Myriad Patents SCOTUS

Senator Leahy Urges NIH to Use March-In Rights on Myriad BRCA Test

On Friday, Sen. Patrick Leahy (D-VT) sent a letter to Dr. Francis Collins, the Director of the National Institutes of Health (NIH), "to urge [the Director] to consider using march-in rights under the Bayh-Dole Act to ensure...more

7/18/2013 - AMP v Myriad Bayh-Dole Act BRCA DNA March-in Myriad NIH Patents USPTO

Reaction to Supreme Court's Decision in AMP v. Myriad

It has been just over two weeks since the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., holding that a naturally occurring DNA segment is a product of nature and not patent...more

7/2/2013 - ACLU AIPLA AMP v Myriad DNA Myriad Patent-Eligible Subject Matter Patents Product of Nature Doctrine

Supreme Court Issues Decision in AMP v. Myriad -- Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

In a much anticipated decision, the Supreme Court issued its opinion this morning in Association for Molecular Pathology v. Myriad Genetics, Inc. In an opinion by Justice Thomas, joined by Chief Justice Roberts, Justices...more

6/14/2013 - AMP v Myriad Biotechnology DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS

USPTO Issues Memo on AMP v. Myriad to Examining Corps

On the same day that the Supreme Court handed down its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Patent and Trademark Office issued a one-page memorandum to its Patent Examining Corps...more

6/14/2013 - AMP v Myriad DNA Human Genes Myriad Patent-Eligible Subject Matter Patents SCOTUS USPTO

Genome Medicine Article Calls for Limits on Patenting of Existing Nucleotide Sequences

In an article published in the current issue of Genome Medicine, Jeffrey Rosenfeld of the University of Medicine & Dentistry of New Jersey and Christopher Mason of Cornell University contend that due to the non-specificity of...more

4/3/2013 - DNA Human Genes Myriad Patent-Eligible Subject Matter Patents

United States Asks Supreme Court to Affirm on cDNA, Reverse on Isolated, Unmodified DNA

In an amicus brief filed last month in Association for Molecular Pathology v. Myriad Genetics, Inc., the United States asks the Supreme Court to affirm the judgment of the Federal Circuit that cDNA is patent-eligible and...more

2/13/2013 - DNA Myriad Patent-Eligible Subject Matter Patents SCOTUS

Top Three Stories of 2012

Reflecting upon the events of the past twelve months, Patent Docs presents its sixth annual list of top biotech/pharma patent stories. For 2012, we identified fifteen stories that were covered on Patent Docs last year that...more

1/4/2013 - America Invents Act DNA Human Genes Mayo v. Prometheus Myriad Patent Reform Patent-Eligible Subject Matter

AMP v. Myriad Briefed and Distributed for Conference - Update

Last week, the Supreme Court updated its docket for the Association for Molecular Pathology v. Myriad Genetics, Inc. case to indicate that it has been distributed for conference on November 30. In response to the Petition...more

11/20/2012 - ACLU Human Genes Myriad Patents SCOTUS

AMP v. Myriad Briefed and Distributed for Conference

Earlier today, the Supreme Court updated its docket for the Association for Molecular Pathology v. Myriad Genetics, Inc. case to indicate that it has now been distributed for conference on November 30. In response to the...more

11/14/2012 - ACLU Human Genes Myriad Patents SCOTUS

20 Results
|
View per page
Page: of 1